Stock SMMT SUMMIT THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Summit Therapeutics Inc.

Equities

SMMT

US86627T1088

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
3.38 USD -21.76% Intraday chart for Summit Therapeutics Inc. -23.87% +29.50%
May. 24 Sector Update: Health Care Stocks Decline Late Friday Afternoon MT
May. 24 Summit Therapeutics Shares Fall After Late-Stage Topline Data for Lung Cancer Treatment Announced MT

Valuation

Fiscal Period: December 2019 2020 2023 2024 2025 2026
Capitalization 1 70.45 282.7 1,437 1,861 - -
Enterprise Value (EV) 1 70.45 282.7 1,437 1,861 1,861 1,861
P/E ratio -9.28 x - -2.62 x - - -
Yield - - - - - -
Capitalization / Revenue 4.47 x 19.4 x - - - 188 x
EV / Revenue 4.47 x 19.4 x - - - 188 x
EV / EBITDA - - - -13.3 x -11.7 x -10.7 x
EV / FCF - - - - - -
FCF Yield - - - - - -
Price to Book - - - - - -
Nbr of stocks (in thousands) 335,890 82,260 700,843 701,980 - -
Reference price 2 1.207 3.437 2.050 2.652 2.652 2.652
Announcement Date 4/30/20 3/17/21 2/20/24 - - -
1GBP in Million2GBP
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2023 2024 2025 2026
Net sales 1 15.75 14.54 - - - 9.927
EBITDA 1 - - - -139.5 -158.8 -174.1
EBIT 1 -25.33 -38.35 - -144.9 -175.4 -218.3
Operating Margin -160.88% -263.7% - - - -2,199.41%
Earnings before Tax (EBT) -25.56 - - - - -
Net income -22.03 - -486.2 - - -
Net margin -139.92% - - - - -
EPS -0.1300 - -0.7828 - - -
Free Cash Flow - - - - - -
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 4/30/20 3/17/21 2/20/24 - - -
1GBP in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 - - - - - -
EBITDA 1 - -35.59 -35.16 -34.82 - -
EBIT 1 -33.85 -36.24 -37.21 -37.43 -41.62 -44.02
Operating Margin - - - - - -
Earnings before Tax (EBT) - - - - - -
Net income - - - - - -
Net margin - - - - - -
EPS - - - - - -
Dividend per Share - - - - - -
Announcement Date 5/1/24 - - - - -
1GBP in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2023 2024 2025 2026
Net Debt - - - - - -
Net Cash position - - - - - -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow - - - - - -
ROE (net income / shareholders' equity) - - - -155% -100% -135%
ROA (Net income/ Total Assets) - - - - - -
Assets - - - - - -
Book Value Per Share - - - - - -
Cash Flow per Share - - - - - -
Capex 1 - - - - - 0.08
Capex / Sales - - - - - 0.8%
Announcement Date 4/30/20 3/17/21 2/20/24 - - -
1GBP in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.652 GBP
Average target price
5.938 GBP
Spread / Average Target
+123.91%
Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
SUMMIT THERAPEUTICS INC. Stock Summit Therapeutics Inc.
+29.50% 2.37B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+12.30% 118B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+12.15% 106B
BIONTECH SE Stock BioNTech SE
-8.14% 23.4B
ARGENX SE Stock argenx SE
-1.69% 21.78B
GENMAB A/S Stock Genmab A/S
-10.60% 18.09B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.25% 16.72B
BEIGENE, LTD. Stock BeiGene, Ltd.
-15.33% 15.97B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.80% 14.03B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+28.03% 11.67B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. SMMT Stock
  4. Financials Summit Therapeutics Inc.